Literature DB >> 28570485

RISK FACTORS FOR RECURRENCES OF CENTRAL SEROUS CHORIORETINOPATHY.

Alexandre Matet1, Alejandra Daruich1, Marta Zola1, Francine Behar-Cohen1,2.   

Abstract

PURPOSE: To describe recurrence patterns and investigate candidate risk factors for recurrences of central serous chorioretinopathy.
METHODS: In 46 patients with acute central serous chorioretinopathy and follow-up >12 months after first episode resolution, parameters influencing recurrences were retrospectively evaluated using a frailty Cox proportional hazard survival model. Covariates included baseline systemic findings: age, gender, corticosteroid use, stress, shift work, sleep disorder, depression, allergy, cardiovascular risk; baseline optical coherence tomography findings: subfoveal choroidal thickness, pigment epithelial detachment pattern (regular/bump/irregular), number of subretinal hyperreflective foci at leakage site; baseline angiographic findings: fluorescein leakage intensity (intense/moderate/subtle/absent), hyperpermeability pattern on indocyanine-green angiography (focal/multifocal); and episode-related findings: duration and treatment of previous episode.
RESULTS: Twenty of 46 subjects (43%) presented ≥1 recurrences during a mean follow-up of 29.9 ± 9.5 months (range, 15-54 months). Follow-up duration did not differ between cases with or without recurrences (P = 0.3). Worse final visual acuity levels (logarithm of the minimal angle of resolution) were associated with a higher number of episodes during follow-up (P = 0.032, r = 0.28). In a univariate analysis, higher subfoveal choroidal thickness (P = 0.021), nonintense fluorescein leakage (= moderate/subtle/absent, P = 0.033), multiple subretinal hyperreflective foci (P = 0.026), and shift work (P < 0.0001) were significantly associated with recurrences, with a near-significant influence of irregular pigment epithelial detachment (P = 0.093). In a multivariate analysis, higher subfoveal choroidal thickness (P = 0.007), nonintense fluorescein leakage (P = 0.003) and shift work (P < 0.0001) remained significant and independent risk factors for recurrences.
CONCLUSION: Multiple factors influence the risk of central serous chorioretinopathy recurrence. These findings may contribute to identify patients at higher risk, who could benefit from earlier or more intensive treatment.

Entities:  

Mesh:

Year:  2018        PMID: 28570485     DOI: 10.1097/IAE.0000000000001729

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  20 in total

Review 1.  [Statement and recommendation of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Situation January 2018].

Authors: 
Journal:  Ophthalmologe       Date:  2018-05       Impact factor: 1.059

2.  Gender variation in central serous chorioretinopathy.

Authors:  Daren Hanumunthadu; Elon H C Van Dijk; Sankeert Gangakhedkar; Abhilash Goud; Chui Ming Gemmy Cheung; Daniel Cherfan; Chintan Sarvaiya; Alay Banker; Catherine Meyerle; Camiel J Boon; Rishi Singh; Lihteh Wu; Jay Chhablani
Journal:  Eye (Lond)       Date:  2018-07-09       Impact factor: 3.775

3.  Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-naïve central serous chorioretinopathy.

Authors:  Mengyang Li; Jinfeng Qu; Zhiqiao Liang; Jiyang Tang; Jie Hu; Yuou Yao; Enzhong Jin; Xiaoxin Li; Mingwei Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-01-13       Impact factor: 3.117

Review 4.  [Statement of the Professional Association of Ophthalmologists in Germany (BVA), the German Ophthalmological Society (DOG) and the Retinological Society (RG) on central serous chorioretinopathy : Status 18 October 2021].

Authors: 
Journal:  Ophthalmologe       Date:  2021-12-14       Impact factor: 1.059

Review 5.  Statement of the Professional Association of Ophthalmologists in Germany (BVA), the German Society of Ophthalmology (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Status 18 October 2021.

Authors: 
Journal:  Ophthalmologie       Date:  2022-04-06

Review 6.  CNGB1-related rod-cone dystrophy: A mutation review and update.

Authors:  Marco Nassisi; Vasily M Smirnov; Cyntia Solis Hernandez; Saddek Mohand-Saïd; Christel Condroyer; Aline Antonio; Laura Kühlewein; Melanie Kempf; Susanne Kohl; Bernd Wissinger; Fadi Nasser; Sara D Ragi; Nan-Kai Wang; Janet R Sparrow; Vivienne C Greenstein; Stylianos Michalakis; Omar A Mahroo; Rola Ba-Abbad; Michel Michaelides; Andrew R Webster; Simona Degli Esposti; Brooke Saffren; Jenina Capasso; Alex Levin; William W Hauswirth; Claire-Marie Dhaenens; Sabine Defoort-Dhellemmes; Stephen H Tsang; Eberhart Zrenner; Jose-Alain Sahel; Simon M Petersen-Jones; Christina Zeitz; Isabelle Audo
Journal:  Hum Mutat       Date:  2021-05-16       Impact factor: 4.700

7.  Choroidal thickness changes in non-treated acute and ranibizumab-treated chronic central serous chorioretinopathy.

Authors:  Erhan Yumusak; Nesrin Buyuktortop Gokcinar; Kemal Ornek
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

8.  Sleep apnea and eye diseases: evidence of association and potential pathogenic mechanisms.

Authors:  Aldara García-Sánchez; Isabel Villalaín; Mónica Asencio; Jesús García; Francisco García-Rio
Journal:  J Clin Sleep Med       Date:  2022-01-01       Impact factor: 4.062

Review 9.  Central Serous Chorioretinopathy and Personality Characteristics: A Systematic Review of Scientific Evidence over the Last 10 Years (2010 to 2020).

Authors:  Giovanni Genovese; Alessandro Meduri; Maria Rosaria Anna Muscatello; Sebastiano Gangemi; Clemente Cedro; Antonio Bruno; Pasquale Aragona; Gianluca Pandolfo
Journal:  Medicina (Kaunas)       Date:  2021-06-16       Impact factor: 2.430

10.  Correlation between Choroidal Neovascularization Shown by OCT Angiography and Choroidal Thickness in Patients with Chronic Central Serous Chorioretinopathy.

Authors:  Joanna Gołębiewska; Joanna Brydak-Godowska; Joanna Moneta-Wielgoś; Monika Turczyńska; Dariusz Kęcik; Wojciech Hautz
Journal:  J Ophthalmol       Date:  2017-10-04       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.